Radiation therapy is a typical treatment for esophageal squamous cell carcinoma (ESCC), especially middle and upper segment esophagus, and inoperable patients. However, how to promote radiation sensitivity in radio-resistant cancer cells is a conundrum. Here, our study investigated the radiosensitizing effect of bortezomib, a specific and reversible dipeptide boronic acid analog, in ESCC cells. Human esophageal squamous carcinoma cell lines Eca109 and TE-13 were exposed to hypoxia and/or ionizing radiation (IR) with or without treatment of bortezomib. Cell proliferation assay was performed with CCK8. Cell apoptosis and cell cycle assay were performed with flow cytometry. The radiosensitization effect of was assessed by clonogenic survival and progression of tumor xenograft. The expression of HIF-1α, VEGF, and apoptosis proteins was evaluated by Western blot. Radiation-induced DNA double strand break and homologous recombination repair were assessed by immunofluorescence. Our results show that bortezomib efficiently radiosensitizes ESCC cells by decreasing the expression of HIF- 1α and VEGF, inducing apoptosis by activating caspase, and delaying DNA damage repair after radiation.
FerlayJ., ShinH.R., BrayF., FormanD., MathersC. and ParkinD.M.Estimates of worldwide burden of cancer in: GLOBOCAN, Int J Cancer127 (2010), 2893–2917.
2.
PennathurA., GibsonM.K., JobeB.A. and LuketichJ.D.Oesophageal carcinoma, Lancet381 (2013), 400–412.
3.
RoederF., NicolayN.H., NguyenT., Saleh-EbrahimiL., AskoxylakisV., BostelT., ZwickerF., DebusJ., TimkeC. and HuberP.E, Intensity modulated radiotherapy (IMRT) with concurrent chemotherapy as definitive treatment of locally advanced esophageal cancer, Radiat Oncol9(1) (2014), 191.
4.
YoshimuraM., ItasakaS., HaradaH. and HiraokaM.Microenvironment and Radiation Therapy, Biomed Res Int (2013), 685308.
5.
ZhangQiu-li, CuiBai-ri, LiHai-yan, PingL., HongL., LiuLi-ping, DingDa-zhi and CuiXun, MAPK and PI3K pathways regulate hypoxia-induced atrial natriuretic peptide secretion by controlling HIF-1 alpha expression in beating rabbit atria, Biochemical and Biophysical Research Communications438 (2013), 507–512.
6.
ReyS. and SemenzaG.L.Hypoxia-inducible factor-1-dependent mechanisms of vascularization and vascular remodeling, Cardiovascular Research86 (2010), 236–242.
7.
SemenzaG.L., Ph.D M.D. Defining the Role of Hypoxia-Inducible Factor 1 in Cancer Biology and Therapeutics, Oncogene29(5) (2010), 625–634.
8.
ShinD.H., ChunY.-S., LeeD.S., HuangL.E. and ParkJ.-W.Bortezomib inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated repression of hypoxia-inducible factor-1, BLOOD111 (2008), 3131–3136.
9.
BefaniC.D., VlachostergiosP.J., HatzidakiE., PatrikidouA., BonanouS., SimosG., PapandreouC.N. and LiakosP.Bortezomib represses HIF-1α protein expression and nuclear accumulation by inhibiting both PI3K/Akt/TOR and MAPK pathways in prostate cancer cells, J Mol Med90 (2012), 45–54.
10.
ChenD., FrezzaM., SchmittS., KanwarJ. and DouQ.P.Bortezomib as the First Proteasome Inhibitor Anticancer Drug: Current Status and Future Perspectives, Curr Cancer Drug Targets11(3) (2011), 239–253.
11.
KamerS., RenQ. and DickerA.P.Differential radiation sensitization of human cervical cancer cell lines by the proteasome inhibitor velcade (bortezomib, PS-341), Arch Gynecol Obstet279(1) (2009), 41–46.
12.
GoelA., DispenzieriA., GreippP.R., WitzigT.E., MesaR.A. and RussellS.J.PS-341-mediated selective targeting of multiple myeloma cells by synergistic increase in ionizing radiation-induced apoptosis, Exp Hematol33(7) (2005), 784–795.
13.
RussoS.M., TepperJ.E., BaldwinA.S.Jr, LiuR., AdamsJ., ElliottP. and CusackJ.C.Jr, Enhancement of radiosensitivity by proteasome inhibition: Implications for a role of NF-kappaB, Int J Radiat Oncol Biol Phys50(1) (2001), 183–193.
14.
WangQ.W., LiuH., LiangY.M., WangT. and ZhuX.D.Proteasome inhibitor bortezomib sensitizes Hep-2 human laryngeal squamous cell carcinoma cells to ionizingradiation in vitro and in vivo, Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi43(6) (2008), 456–459.
15.
GoktasS., BaranY. and UralA.U.et al., Proteasome inhibitor bortezomib increases radiation sensitivity in androgen independent human prostate cancer cells, Urology75(4) (2010), 793–798.
16.
CronK.R., ZhuK., KushwahaD.S., HsiehG. and MerzonD.et al., Proteasome Inhibitors Block DNA Repair and Radiosensitize Non-Small Cell Lung Cancer, PLoS ONE8(9) (2013), e73710, doi: 10.1371/journal.pone.0073710
17.
GoelA., DispenzieriA., GreippP.R., WitzigT.E., MesaR.A. and RussellS.J.PS-341-mediated selective targeting of multiple myeloma cells by synergistic increase in ionizing radiation-induced apoptosis, Exp Hematol33(7) (2005), 784–795.
18.
RussoS.M., TepperJ.E. and BaldwinA.S.Jret al., Enhancement of radiosensitivity by proteasome inhibition: Implications for a role of NF-kappaB, Int J Radiat Oncol Biol Phys50(1) (2001), 183–193.
19.
TangN., WangL. and EskoJ.et al., Loss of HIF-1α in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis, Cancer Cell6(5) (2004), 485–495.
20.
RichardD.E., BerraE. and PouysségurJ.Angiogenesis: How a tumor adapts to hypoxia, Biochemical and Biophysical Research Communications266(3) (1999), 718–722.
21.
MeijerT.W. and KaandersJ.H.et al., Targeting hypoxia, HIF-1, and tumor glucose metabolism to improve radiotherapy efficacy, J Clin Cancer Res: Off J Am Assoc Cancer Res18 (2012), 5585–5594.
22.
BelozerovV.E. and Van MeirE.G.Hypoxia inducible factor-1: A novel target for cancer therapy[J], Anti-Cancer Drugs16 (2005), 901–909.
23.
MeijerT.W., KaandersJ.H., SpanP.N. and BussinkJ.Targeting hypoxia, HIF-1, and tumor glucose metabolism to improve radiotherapy efficacy, Clin Cancer Res18 (2012), 5585–5594.
24.
OrlowskiR.Z. and KuhnD.J.Proteasome inhibitors in cancer therapy: Lessons from the first decade, Clin Cancer Res14 (1657), 1649–1657.
